These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24982338)

  • 21. RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway.
    Zhang F; Wang Z; Yuan J; Wei X; Tian R; Niu R
    Breast Cancer Res Treat; 2015 Sep; 153(2):263-75. PubMed ID: 26253946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
    Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
    Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth.
    Ueyama K; Ikeda K; Sato W; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
    Cancer Gene Ther; 2010 Sep; 17(9):624-32. PubMed ID: 20467453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockdown of interferon-induced transmembrane protein 3 expression suppresses breast cancer cell growth and colony formation and affects the cell cycle.
    Yang M; Gao H; Chen P; Jia J; Wu S
    Oncol Rep; 2013 Jul; 30(1):171-8. PubMed ID: 23624618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Growth inhibition of MG-63 cells by cyclin A2 gene-specific small interfering RNA].
    Liu Y; Fan SW; Ding JY; Zhao X; Shen WL
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(9):627-33. PubMed ID: 17550735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells.
    Zhu J; Li QY; Liu JL; Wei W; Yang HW; Tang W
    Oncol Rep; 2015 Dec; 34(6):3156-62. PubMed ID: 26397146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1.
    Yde CW; Issinger OG
    Int J Oncol; 2006 Dec; 29(6):1397-404. PubMed ID: 17088977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoproteomic comparison of clinical triple-negative and luminal breast tumors.
    Hill JJ; Tremblay TL; Fauteux F; Li J; Wang E; Aguilar-Mahecha A; Basik M; O'Connor-McCourt M
    J Proteome Res; 2015 Mar; 14(3):1376-88. PubMed ID: 25658377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
    Chen J; Chung F; Yang G; Pu M; Gao H; Jiang W; Yin H; Capka V; Kasibhatla S; Laffitte B; Jaeger S; Pagliarini R; Chen Y; Zhou W
    Oncotarget; 2013 Dec; 4(12):2502-11. PubMed ID: 24318446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. siRNA Library Screening to Identify Complementary Therapeutic Pairs in Triple-Negative Breast Cancer Cells.
    Thapa B; Remant KC; Uludağ H
    Methods Mol Biol; 2019; 1974():1-19. PubMed ID: 31098991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation.
    Silina L; Dufour F; Rapinat A; Reyes C; Gentien D; Maksut F; Radvanyi F; Verrelle P; Bernard-Pierrot I; Mégnin-Chanet F
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TYRO3: A potential therapeutic target in cancer.
    Hsu PL; Jou J; Tsai SJ
    Exp Biol Med (Maywood); 2019 Feb; 244(2):83-99. PubMed ID: 30714403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth.
    Abbud-Antaki RA; Marhefka JN; DeLuca AL; Zuromskis MP
    Horm Cancer; 2012 Dec; 3(5-6):261-70. PubMed ID: 22689254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
    Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
    J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
    Suh YA; Jo SY; Lee HY; Lee C
    Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.